The rise and fall of insulin secretion in type 1 diabetes mellitus

[1]  J. Stockman.  Insulin Needs After CD3-Antibody Therapy in New-Onset Type 1 Diabetes , 2007 .

[2]  K. Herold,et al.  Natural history of beta-cell function in type 1 diabetes. , 2005, Diabetes.

[3]  I. Rooman,et al.  Regulation of pancreatic beta-cell mass. , 2005, Physiological reviews.

[4]  J. Brun,et al.  Limited accuracy of surrogates of insulin resistance during puberty in obese and lean children at risk for altered glucoregulation. , 2005, The Journal of clinical endocrinology and metabolism.

[5]  P. Raskin,et al.  Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. , 2005, Diabetes care.

[6]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[7]  Xiang Yan,et al.  Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes. , 2005, World journal of gastroenterology.

[8]  J. Krischer,et al.  Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. , 2005, Diabetes care.

[9]  O. Faber,et al.  B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment , 1977, Diabetologia.

[10]  G. Reaven,et al.  Impact of degree of obesity on surrogate estimates of insulin resistance. , 2004, Diabetes care.

[11]  G. A. Fleming,et al.  Erratum: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: Report of an ADA workshop, 21-22 October 2001 (Diabetes (2004) 53 (250-264)) , 2004 .

[12]  J. She,et al.  Preservation of C‐peptide secretion in subjects at high risk of developing type 1 diabetes mellitus – a new surrogate measure of non‐progression? , 2004, Pediatric diabetes.

[13]  D. Harlan,et al.  Insulin secretion in type 1 diabetes. , 2004, Diabetes.

[14]  Å. Lernmark,et al.  Islet cell antibodies are associated withβ-cell failure also in obese adult onset diabetic patients , 1994, Acta Diabetologica.

[15]  Å. Lernmark,et al.  Factors influencing the magnitude, duration, and rate of fall of B-cell function in Type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis , 1988, Diabetologia.

[16]  M. Löhr,et al.  Residual insulin positivity and pancreatic atrophy in relation to duration of chronic Type 1 (insulin-dependent) diabetes mellitus and microangiopathy , 1987, Diabetologia.

[17]  G. A. Fleming,et al.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. , 2004, Diabetes.

[18]  D. Drucker,et al.  Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. , 2003, Diabetes.

[19]  L. Romics,et al.  Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. , 2003, Diabetes care.

[20]  J. Killestein.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[21]  M. Landin-Olsson.  Latent Autoimmune Diabetes in Adults , 2002, Annals of the New York Academy of Sciences.

[22]  I. Cohen,et al.  β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial , 2001, The Lancet.

[23]  D. Jacobs,et al.  Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. , 2001, The Journal of pediatrics.

[24]  B. Gower,et al.  Longitudinal study on pubertal insulin resistance. , 2001, Diabetes.

[25]  R. Saad,et al.  Dihydrotestosterone treatment in adolescents with delayed puberty: does it explain insulin resistance of puberty? , 2001, The Journal of clinical endocrinology and metabolism.

[26]  I. Cohen,et al.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. , 2001, Lancet.

[27]  L. Jovanovič,et al.  Is the paradoxical first trimester drop in insulin requirement due to an increase in C-peptide concentration in pregnant Type I diabetic women? , 2000, Diabetologia.

[28]  S. Bonner-Weir.  Islet growth and development in the adult. , 2000, Journal of molecular endocrinology.

[29]  S. Bonner-Weir.  Perspective: Postnatal pancreatic beta cell growth. , 2000, Endocrinology.

[30]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[31]  D. Jacobs,et al.  Insulin resistance during puberty: results from clamp studies in 357 children. , 1999, Diabetes.

[32]  K. Polonsky,et al.  Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. , 1999, Diabetes.

[33]  D. Kendall,et al.  Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. , 1998, Diabetes.

[34]  K. Polonsky,et al.  Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. , 1998, Diabetes.

[35]  R. Holman,et al.  UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes , 1997, The Lancet.

[36]  J. Janosky,et al.  Insulin secretion and sensitivity in black versus white prepubertal healthy children. , 1997, The Journal of clinical endocrinology and metabolism.

[37]  S. Bonner-Weir,et al.  Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. , 1997, Endocrinology.

[38]  C. Kahn,et al.  Development of a Novel Polygenic Model of NIDDM in Mice Heterozygous for IR and IRS-1 Null Alleles , 1997, Cell.

[39]  S. Bonner-Weir,et al.  Dynamics of β-cell Mass in the Growing Rat Pancreas: Estimation With a Simple Mathematical Model , 1995, Diabetes.

[40]  S. Bonner-Weir,et al.  Transplanted beta cell response to increased metabolic demand. Changes in beta cell replication and mass. , 1994, The Journal of clinical investigation.

[41]  L. Baxter,et al.  A Second Pathway for Regeneration of Adult Exocrine and Endocrine Pancreas: A Possible Recapitulation of Embryonic Development , 1993, Diabetes.

[42]  A. Stene,et al.  Effects of maturational stage on insulin sensitivity during puberty. , 1993, The Journal of clinical endocrinology and metabolism.

[43]  A. Schiffrin,et al.  Factors Predicting Course of β-cell Function in IDDM , 1992, Diabetes Care.

[44]  O. Snorgaard,et al.  Homogeneity in Pattern of Decline of β-Cell Function in IDDM: Prospective study of 204 consecutive cases followed for 7.4 yr , 1992, Diabetes Care.

[45]  S. Caprio,et al.  Growth hormone and insulin interactions. , 1992, Hormone research.

[46]  A. Schiffrin,et al.  Factors predicting course of beta-cell function in IDDM. , 1992, Diabetes care.

[47]  W. Tamborlane,et al.  Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. , 1991, The Journal of clinical endocrinology and metabolism.

[48]  W. Tamborlane,et al.  Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. , 1989, The Journal of pediatrics.

[49]  J. Leahy,et al.  Compensatory Growth of Pancreatic β-Cells in Adult Rats After Short-Term Glucose Infusion , 1989, Diabetes.

[50]  M. Horlick,et al.  Recovery of beta-cell function postpartum in a patient with insulin-dependent diabetes mellitus. , 1988, New York state journal of medicine.

[51]  K. Polonsky,et al.  Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[52]  B H Frank,et al.  Quantitative study of insulin secretion and clearance in normal and obese subjects. , 1988, The Journal of clinical investigation.

[53]  D. Daneman,et al.  Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.

[54]  C. Bloch,et al.  Puberty decreases insulin sensitivity. , 1987, The Journal of pediatrics.

[55]  D. Becker,et al.  Residual β-Cell Function in Children With IDDM: Reproducibility of Testing and Factors Influencing Insulin Secretory Reserve , 1987, Diabetes Care.

[56]  W. Tamborlane,et al.  Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. , 1986, The New England journal of medicine.

[57]  K. Polonsky,et al.  The Limitations to and Valid Use of C-Peptide as a Marker of the Secretion of Insulin , 1986, Diabetes.

[58]  Bruce H. Frank,et al.  Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. , 1986, The Journal of clinical investigation.

[59]  G. Eisenbarth,et al.  Type I diabetes mellitus: a chronic autoimmune disease? , 1984, Pediatric clinics of North America.

[60]  C. Christiansen,et al.  Beta-cell function and metabolic control in insulin treated diabetics. , 1980, Acta endocrinologica.

[61]  O. Faber,et al.  C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus , 1977, Diabetes.

[62]  J. Ludvigsson,et al.  C‐PEPTIDE IN JUVENILE DIABETICS BEYOND THE POSTINITIAL REMISSION PERIOD Relation to Clinical Manifestations at Onset of Diabetes, Remission and Diabetic Control , 1977, Acta paediatrica Scandinavica.